Tulane University
To assess the safety and effectiveness of renal artery denervation with subsequent splanchnic nerves denervation via catheter-based radiofrequency ablation in improving blood pressure and glycemic control in patients with resistant hypertension and type 2 diabetes.
The investigators propose a multicenter, prospective, single blind, randomized controlled pilot study. Patients with treatment-resistant hypertension and diabetes mellitus type 2 will be enrolled to undergo renal artery denervation with subsequent splanchnic nerves denervation for lowering blood pressure and glycemic levels. 20 patients will be randomly selected from outpatient cardiology clinics and will be assigned (1:1) to receive an FDA approved catheter-based denervation (CDN) of the renal arteries or CDN of the renal arteries with subsequent CDN of the splanchnic nerves at the level of…
Inclusion Criteria: * Patients aged 18-75. * History of Type 2 Diabetes Mellitus at least 5 years prior to enrollment. * HbA1c level ≥6.5% * Use of at least 1 oral antidiabetic agent and no changes in the last 30 days. * History of essential hypertension with systolic Blood pressure of 160 mmHg or more (≥150 mmHg in patient with Type 2 Diabetes Mellitus), despite compliance with three of more antihypertensive drugs. * Stable drug regimen of at least 3 antihypertensive medications with no changes for 2 weeks before enrollment. Exclusion Criteria: * Estimated glomerular filtration rate of les…
Catheter-based endovascular denervation (CDN) of renal arteries and splanchnic nerves (celiac + SMA) using radiofrequency ablation
Catheter-based endovascular denervation (CDN) of renal arteries only, without splanchnic nerve denervation
Arctuva estimate
Verify or correct the compensation shown for this listing.